OBJECTIVES: New classes of drugs are needed to treat tuberculosis (TB) in order to combat the emergence of resistance to existing agents and shorten the duration of therapy. Targeting DNA gyrase is a clinically validated therapeutic approach using fluoroquinolone antibiotics to target the gyrase subunit A (GyrA) of the heterotetramer. Increasing resistance to fluoroquinolones has driven interest in targeting the gyrase subunit B (GyrB), which has not been targeted for TB. The biological activities of two potent small-molecule inhibitors of GyrB have been characterized to validate its targeting as a therapeutic strategy for treating TB. MATERIALS AND METHODS: Novobiocin and aminobenzimidazole 1 (AB-1) were tested for their activity against Mycobacterium tuberculosis (Mtb) H37Rv and other mycobacteria. AB-1 and novobiocin were also evaluated for their interaction with rifampicin and isoniazid as well as their potential for cytotoxicity. Finally, AB-1 was tested for in vivo efficacy in a murine model of TB. RESULTS: Novobiocin and AB-1 have both been shown to be active against Mtb with MIC values of 4 and 1 mg/L, respectively. Only AB-1 exhibited time-dependent bactericidal activity against drug-susceptible and drug-resistant mycobacteria, including a fluoroquinolone-resistant strain. AB-1 had potent activity in the low oxygen recovery assay model for non-replicating persistent Mtb. Additionally, AB-1 has no interaction with isoniazid and rifampicin, and has no cross-resistance with fluoroquinolones. In a murine model of TB, AB-1 significantly reduced lung cfu counts in a dose-dependent manner. CONCLUSIONS: Aminobenzimidazole inhibitors of GyrB exhibit many of the characteristics required for their consideration as a potential front-line antimycobacterial therapeutic.
OBJECTIVES: New classes of drugs are needed to treat tuberculosis (TB) in order to combat the emergence of resistance to existing agents and shorten the duration of therapy. Targeting DNA gyrase is a clinically validated therapeutic approach using fluoroquinolone antibiotics to target the gyrase subunit A (GyrA) of the heterotetramer. Increasing resistance to fluoroquinolones has driven interest in targeting the gyrase subunit B (GyrB), which has not been targeted for TB. The biological activities of two potent small-molecule inhibitors of GyrB have been characterized to validate its targeting as a therapeutic strategy for treating TB. MATERIALS AND METHODS:Novobiocin and aminobenzimidazole 1 (AB-1) were tested for their activity against Mycobacterium tuberculosis (Mtb) H37Rv and other mycobacteria. AB-1 and novobiocin were also evaluated for their interaction with rifampicin and isoniazid as well as their potential for cytotoxicity. Finally, AB-1 was tested for in vivo efficacy in a murine model of TB. RESULTS:Novobiocin and AB-1 have both been shown to be active against Mtb with MIC values of 4 and 1 mg/L, respectively. Only AB-1 exhibited time-dependent bactericidal activity against drug-susceptible and drug-resistant mycobacteria, including a fluoroquinolone-resistant strain. AB-1 had potent activity in the low oxygen recovery assay model for non-replicating persistent Mtb. Additionally, AB-1 has no interaction with isoniazid and rifampicin, and has no cross-resistance with fluoroquinolones. In a murine model of TB, AB-1 significantly reduced lung cfu counts in a dose-dependent manner. CONCLUSIONS:Aminobenzimidazole inhibitors of GyrB exhibit many of the characteristics required for their consideration as a potential front-line antimycobacterial therapeutic.
Authors: Trudy H Grossman; Douglas J Bartels; Steve Mullin; Christian H Gross; Jonathan D Parsons; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Eric R Olson; Paul S Charifson; Nagraj Mani Journal: Antimicrob Agents Chemother Date: 2006-11-20 Impact factor: 5.191
Authors: Paul S Charifson; Anne-Laure Grillot; Trudy H Grossman; Jonathan D Parsons; Michael Badia; Steve Bellon; David D Deininger; Joseph E Drumm; Christian H Gross; Arnaud LeTiran; Yusheng Liao; Nagraj Mani; David P Nicolau; Emanuele Perola; Steven Ronkin; Dean Shannon; Lora L Swenson; Qing Tang; Pamela R Tessier; Ski-Kai Tian; Martin Trudeau; Tiansheng Wang; Yunyi Wei; Hong Zhang; Dean Stamos Journal: J Med Chem Date: 2008-08-09 Impact factor: 7.446
Authors: Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Richard J O'Brien; Andrew N Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset Journal: Am J Respir Crit Care Med Date: 2003-10-24 Impact factor: 21.405
Authors: Marcus B Conde; Anne Efron; Carla Loredo; Gilvan R Muzy De Souza; Nadja P Graça; Michelle C Cezar; Malathi Ram; Mohammad A Chaudhary; William R Bishai; Afranio L Kritski; Richard E Chaisson Journal: Lancet Date: 2009-04-04 Impact factor: 79.321
Authors: D A Scudiero; R H Shoemaker; K D Paull; A Monks; S Tierney; T H Nofziger; M J Currens; D Seniff; M R Boyd Journal: Cancer Res Date: 1988-09-01 Impact factor: 12.701
Authors: T B K Reddy; Robert Riley; Farrell Wymore; Phillip Montgomery; Dave DeCaprio; Reinhard Engels; Marcel Gellesch; Jeremy Hubble; Dennis Jen; Heng Jin; Michael Koehrsen; Lisa Larson; Maria Mao; Michael Nitzberg; Peter Sisk; Christian Stolte; Brian Weiner; Jared White; Zachariah K Zachariah; Gavin Sherlock; James E Galagan; Catherine A Ball; Gary K Schoolnik Journal: Nucleic Acids Res Date: 2008-10-03 Impact factor: 16.971
Authors: Christopher P Locher; Steven M Jones; Brian L Hanzelka; Emanuele Perola; Carolyn M Shoen; Michael H Cynamon; Andile H Ngwane; Ian J Wiid; Paul D van Helden; Fabrice Betoudji; Eric L Nuermberger; John A Thomson Journal: Antimicrob Agents Chemother Date: 2014-12-22 Impact factor: 5.191
Authors: Jozef Stec; Catherine Vilchèze; Shichun Lun; Alexander L Perryman; Xin Wang; Joel S Freundlich; William Bishai; William R Jacobs; Alan P Kozikowski Journal: ChemMedChem Date: 2014-08-27 Impact factor: 3.466
Authors: Erika Kapp; Hanri Visser; Samantha L Sampson; Sarel F Malan; Elizabeth M Streicher; Germaine B Foka; Digby F Warner; Sylvester I Omoruyi; Adaze B Enogieru; Okobi E Ekpo; Frank T Zindo; Jacques Joubert Journal: Molecules Date: 2017-09-30 Impact factor: 4.411